Hugo Arias-Pulido

Summary

Affiliation: University of New Mexico
Country: USA

Publications

  1. pmc GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer
    Hugo Arias-Pulido
    Translational Therapeutics Laboratory, The University of New Mexico Cancer Center, Albuquerque, NM, USA
    Breast Cancer Res Treat 123:51-8. 2010
  2. pmc Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients
    Nabila Chaher
    Department of Pathology, Centre Pierre et Marie Curie, 1, Avenue Battendier, Place May 1st, Algiers, Algeria
    Breast Cancer Res Treat 131:437-44. 2012
  3. pmc Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer
    Hugo Arias-Pulido
    Department of Internal Medicine, The University of New Mexico Cancer Center, Albuquerque, NM, USA
    BMC Cancer 12:298. 2012
  4. pmc Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma
    Pulivarthi H Rao
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX, USA
    BMC Cancer 4:5. 2004
  5. ncbi Human papillomavirus type 18 variant lineages in United States populations characterized by sequence analysis of LCR-E6, E2, and L1 regions
    Hugo Arias-Pulido
    Department of Molecular Genetics and Microbiology, University of New Mexico, Health Sciences Center, School of Medicine, Albuquerque, NM 87111, USA
    Virology 338:22-34. 2005
  6. pmc Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors
    Hugo Arias-Pulido
    Translational Therapeutics Laboratory, The University of New Mexico Cancer Center, Albuquerque, NM 87131 5636, USA
    Gynecol Oncol 114:480-5. 2009
  7. ncbi Absence of epidermal growth factor receptor mutations in cervical cancer
    H Arias-Pulido
    Department of Pathology, Division of Hematology Oncology, The University of New Mexico Cancer Center, Albuquerque, New Mexico
    Int J Gynecol Cancer 18:749-54. 2008
  8. pmc Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha
    Luigi Scotto
    Department of Pathology, Columbia University Medical Center, New York, New York, USA
    Mol Cancer 7:58. 2008
  9. pmc Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer
    Gopeshwar Narayan
    Department of Pathology, Columbia University Medical Center, New York, NY 10032, USA
    Genes Chromosomes Cancer 48:983-92. 2009
  10. pmc Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome
    Gopeshwar Narayan
    Department of Pathology, Columbia University, New York, New York 10032, USA
    Mol Cancer 2:24. 2003

Detail Information

Publications21

  1. pmc GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer
    Hugo Arias-Pulido
    Translational Therapeutics Laboratory, The University of New Mexico Cancer Center, Albuquerque, NM, USA
    Breast Cancer Res Treat 123:51-8. 2010
    ..These findings suggest potential new therapeutic targets for IBC such as novel endocrine agents or direct modulation of GPR30...
  2. pmc Molecular and epidemiological characteristics of inflammatory breast cancer in Algerian patients
    Nabila Chaher
    Department of Pathology, Centre Pierre et Marie Curie, 1, Avenue Battendier, Place May 1st, Algiers, Algeria
    Breast Cancer Res Treat 131:437-44. 2012
    ..Current therapeutic treatments were not very effective in this population and new approaches are much needed...
  3. pmc Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer
    Hugo Arias-Pulido
    Department of Internal Medicine, The University of New Mexico Cancer Center, Albuquerque, NM, USA
    BMC Cancer 12:298. 2012
    ....
  4. pmc Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma
    Pulivarthi H Rao
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX, USA
    BMC Cancer 4:5. 2004
    ..Therefore, genetic characterization is essential for understanding the biology and clinical heterogeneity in cervical cancer (CC)...
  5. ncbi Human papillomavirus type 18 variant lineages in United States populations characterized by sequence analysis of LCR-E6, E2, and L1 regions
    Hugo Arias-Pulido
    Department of Molecular Genetics and Microbiology, University of New Mexico, Health Sciences Center, School of Medicine, Albuquerque, NM 87111, USA
    Virology 338:22-34. 2005
    ..Several novel HPV 18 nucleotide variations were identified in this study...
  6. pmc Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors
    Hugo Arias-Pulido
    Translational Therapeutics Laboratory, The University of New Mexico Cancer Center, Albuquerque, NM 87131 5636, USA
    Gynecol Oncol 114:480-5. 2009
    ..This study was conducted to determine if ER and PR expression patterns are predictive of outcome in patients with epithelial ovarian cancer (EOC) or ovarian low malignant potential (LMP) tumors...
  7. ncbi Absence of epidermal growth factor receptor mutations in cervical cancer
    H Arias-Pulido
    Department of Pathology, Division of Hematology Oncology, The University of New Mexico Cancer Center, Albuquerque, New Mexico
    Int J Gynecol Cancer 18:749-54. 2008
    ..Our results suggest, therefore, that treatment of CC patients with TKIs may not have the same efficacy as seen in patients with lung cancer, and that targeting the EGFR with other inhibitors may be more appropriate...
  8. pmc Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha
    Luigi Scotto
    Department of Pathology, Columbia University Medical Center, New York, New York, USA
    Mol Cancer 7:58. 2008
    ..These changes may possess oncogenic properties by deregulating tumor-related genes. Gain of short arm of chromosome 5 (5p) is the most frequent karyotypic change in CC...
  9. pmc Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer
    Gopeshwar Narayan
    Department of Pathology, Columbia University Medical Center, New York, NY 10032, USA
    Genes Chromosomes Cancer 48:983-92. 2009
    ..Our studies demonstrate that inactivation of PCDH10 may be a critical event in CC progression and form a potentially useful therapeutic target for CC...
  10. pmc Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome
    Gopeshwar Narayan
    Department of Pathology, Columbia University, New York, New York 10032, USA
    Mol Cancer 2:24. 2003
    ..Although a host of genetic alterations have been identified, molecular basis of CC development is still poorly understood...
  11. pmc Mapping common deleted regions on 5p15 in cervical carcinoma and their occurrence in precancerous lesions
    Hugo Arias-Pulido
    Department of Pathology, College of Physicians and Surgeons of Columbia University, 630 West 168th Street, New York, 10032, USA
    Mol Cancer 1:3. 2002
    ..These data therefore suggest that loss of candidate tumor suppressor genes located on 5p is associated with the development of CC. However, the precise location of 5p deletions is not known...
  12. pmc Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer
    Hugo Arias-Pulido
    Department of Molecular Genetics and Microbiology, School of Medicine, Health Sciences Center, University of New Mexico, Albuquerque, NM 87111, USA
    J Clin Microbiol 44:1755-62. 2006
    ..HPV-16 E2 expressed from intact episomes may act in trans to regulate integrated genome expression of E6 and E7...
  13. ncbi Promoter hypermethylation of FANCF: disruption of Fanconi Anemia-BRCA pathway in cervical cancer
    Gopeshwar Narayan
    Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, New York 10032, USA
    Cancer Res 64:2994-7. 2004
    ..Thus, these results have important implications in understanding the molecular basis of CC tumorigenesis and clinical management in designing targeted experimental therapeutic protocols...
  14. pmc Promoter hypermethylation-mediated inactivation of multiple Slit-Robo pathway genes in cervical cancer progression
    Gopeshwar Narayan
    Department of Pathology, College of Physicians and Surgeons of Columbia University, New York, NY, USA
    Mol Cancer 5:16. 2006
    ..Slit genes mediate their effect by binding to its receptor Roundabout (Robo). These genes have shown to be inactivated by promoter hypermethylation in a number of human cancers...
  15. ncbi Gene dosage alterations revealed by cDNA microarray analysis in cervical cancer: identification of candidate amplified and overexpressed genes
    Gopeshwar Narayan
    Department of Pathology, Columbia University Medical Center, NY 10032, USA
    Genes Chromosomes Cancer 46:373-84. 2007
    ..These data, thus, form an important step toward the identification of biologically relevant genes in CC pathogenesis. This article contains Supplementary Material available at http://www.interscience.wiley.com/jpages/1045-2257/suppmat...
  16. pmc A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer
    Julie E Bauman
    Department of Internal Medicine, Division of Hematology Oncology and Biostatistics, University of New Mexico Cancer Center, Albuquerque, New Mexico, USA
    BMC Cancer 12:449. 2012
    ..Antagonizing PDGFR with imatinib may improve intra-tumoral delivery of paclitaxel, increasing response rate (RR)...
  17. pmc A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma
    Julie E Bauman
    Department of Internal Medicine, Division of Hematology Oncology, University of Pittsburgh, Pittsburgh, PA, USA
    Oral Oncol 49:461-7. 2013
    ..Downstream activation of the PI3K/Akt/mTOR pathway is an established resistance mechanism. Concurrent mTOR blockade may improve efficacy of anti-EGFR therapy...
  18. ncbi Loss of heterozygosity on chromosome 6 in HPV-16 positive cervical carcinomas carrying the DRB1*1501-DQB1*0602 haplotype
    Hugo Arias-Pulido
    Department of Molecular Genetics and Microbiology, University of New Mexico, Health Sciences Center, School of Medicine, Albuquerque, New Mexico 87131, USA
    Genes Chromosomes Cancer 40:277-84. 2004
    ..These losses may be a reflection of both an abnormal immune response and a general genome-wide instability resulting from virus persistence...
  19. doi Mesothelin and GPR30 staining among a spectrum of pancreatic epithelial neoplasms
    Joseph P Glass
    University of New Mexico, Albuquerque, NM, USA
    Int J Surg Pathol 19:588-96. 2011
    ..Our study attempts to characterize mesothelin and GPR30 / estrogen receptor (ER) staining in pancreatic pathology...
  20. doi Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression
    Luigi Scotto
    Department of Pathology, Columbia University Medical Center, New York, NY 10032, USA
    Genes Chromosomes Cancer 47:755-65. 2008
    ..Our findings implicate a role for these genes in CC tumorigenesis, represent an important step toward the development of clinically significant biomarkers, and form a framework for testing as molecular therapeutic targets...
  21. doi Novel chemotherapy approaches for cervical cancer
    Sujana Movva
    Cancer Research and Treatment Center, University of New Mexico, Albuquerque, New Mexico, USA
    Cancer 115:3166-80. 2009
    ..The use of novel therapeutic approaches targeted to the carcinogenic processes that leads to the ontogenesis of cervical cancer should be promoted in clinical studies to improve patient outcomes...